TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Effect of Tadalafil Once Daily for 8 Weeks on Prostatic Blood Flow and Perfusion Parameters in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
Brief Summary: The purpose of this trial is to evaluate the effect of tadalafil 5 milligrams (mg) daily for 8 weeks compared to placebo on prostatic blood perfusion in men with signs and symptoms of Benign Prostatic Hyperplasia (BPH), measured by resistive index (RI) in the prostate transition zone.


Options:
A: Arm Label: 5 milligrams (mg) Tadalafil; Type: EXPERIMENTAL; Interventions: Drug: Tadalafil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tadalafil; Assigned to Arm(s): 5 milligrams (mg) Tadalafil | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo tablet, Drug: Placebo capsule | Arm Label: Tadalafil 5 milligram (mg); Type: EXPERIMENTAL; Interventions: Drug: Tadalafil 5 mg | Arm Label: Tamsulosin 0.4 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tamsulosin | Intervention Type: DRUG; Name: Tadalafil 5 mg; Assigned to Arm(s): Tadalafil 5 milligram (mg) | Intervention Type: DRUG; Name: Placebo tablet; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Tamsulosin; Assigned to Arm(s): Tamsulosin 0.4 mg | Intervention Type: DRUG; Name: Placebo capsule; Assigned to Arm(s): Placebo
C: Arm Label: Tadalafil; Type: EXPERIMENTAL; Interventions: Drug: tadalafil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): Tadalafil
D: Intervention Type: DRUG; Name: Viagra; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Measuring Quality of Decisions About Treatment of Depression
Brief Summary: The purpose of this randomized controlled trial is to examine the impact of a patient decision aid on the quality of decisions about managing symptoms of depression. In particular, we will examine whether the decision aid increases knowledge about depression/managing depression symptoms and concordance between goals and treatment choices.


Options:
A: Arm Label: Computerized Decision Support System (CDSS); Type: EXPERIMENTAL; Interventions: Other: Computerized Decision Support System | Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Computerized Decision Support System; Assigned to Arm(s): Computerized Decision Support System (CDSS)
B: Arm Label: CBT preference arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive-behavioral therapy | Arm Label: Yoga preference arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Yoga | Arm Label: CBT randomized arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive-behavioral therapy | Arm Label: Yoga randomized arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Yoga | Intervention Type: BEHAVIORAL; Name: Cognitive-behavioral therapy; Assigned to Arm(s): CBT preference arm, CBT randomized arm | Intervention Type: BEHAVIORAL; Name: Yoga; Assigned to Arm(s): Yoga preference arm, Yoga randomized arm
C: Arm Label: Deep Brain Stimulation; Type: EXPERIMENTAL; Interventions: Device: Deep Brain Stimulation | Intervention Type: DEVICE; Name: Deep Brain Stimulation; Assigned to Arm(s): Deep Brain Stimulation
D: Arm Label: Decision Aid; Type: EXPERIMENTAL; Interventions: Behavioral: DVD/Booklet: Coping with Symptoms of Depression | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: DVD/Booklet: Coping with Symptoms of Depression; Assigned to Arm(s): Decision Aid

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Considering Patient Diet Preference to Optimize Weight Loss
Brief Summary: Obesity is increasingly common and can lead to decreased quality of life, increased medical and psychiatric illness, high health care costs, and early mortality. The problem of obesity is as great in veterans as it is in the general public. Adherence to dietary therapy for obesity is often inadequate, possibly because patients' food preferences are not considered during dietary counseling. Allowing patients to choose a diet based on their food preferences may increase their motivation to adhere to diet counseling. This, in turn, could enhance their weight loss success and, ultimately, reduce the many health complications and costs of obesity. The proposed study will examine whether assessing a person's food preferences, and then allowing the person to choose from two commonly prescribed diets, results in greater weight loss success.


Options:
A: Intervention Type: BEHAVIORAL; Name: Diet counseling; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: dietary intervention; Assigned to Arm(s): N/A
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Choice | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Choice; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Arm 2
D: Intervention Type: BEHAVIORAL; Name: Four Diets Differing in Macronutrient Composition; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Diets Low in Saturated Fat; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Miami Healthy Heart Initiative (MHHI) a Randomized Study of Behavioral Risk Factors for Cardiovascular Disease in Latino and Hispanic Patients With Poorly Controlled Diabetes
Brief Summary: A study to examine the effectiveness of a multilevel Community Health Workers intervention as an adjunct to routine primary care in reducing CVD risk factors among diabetic Latinos in Miami.


Options:
A: Arm Label: Walking Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Walking Intervention | Arm Label: Wait-list control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Walking Intervention; Assigned to Arm(s): Walking Intervention
B: Arm Label: Community Health Worker Model; Type: EXPERIMENTAL; Interventions: Behavioral: CARIÑO Project | Arm Label: Enhanced Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced Usual Care | Intervention Type: BEHAVIORAL; Name: CARIÑO Project; Assigned to Arm(s): Community Health Worker Model | Intervention Type: BEHAVIORAL; Name: Enhanced Usual Care; Assigned to Arm(s): Enhanced Usual Care
C: Arm Label: Group Based; Type: EXPERIMENTAL; Interventions: Behavioral: Group-Based (GB) Intervention | Arm Label: Home-Based; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Home-Based (HB) Intervention | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Group-Based (GB) Intervention; Assigned to Arm(s): Group Based | Intervention Type: BEHAVIORAL; Name: Home-Based (HB) Intervention; Assigned to Arm(s): Home-Based
D: Arm Label: Patient Navigation (PN); Type: EXPERIMENTAL; Interventions: Behavioral: Patient Navigation | Arm Label: Usual Care (UC); Type: OTHER; Interventions: Other: Usual Care | Intervention Type: BEHAVIORAL; Name: Patient Navigation; Assigned to Arm(s): Patient Navigation (PN) | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care (UC)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Double Blind, Exploratory, Parallel-group, Placebocontrolled Clinical Study to Assess Two Dosing Regimens of GSK2402968 for Efficacy, Safety, Tolerability and Pharmacokinetics in Ambulant Subjects With Duchenne Muscular Dystrophy
Brief Summary: The purpose of this study is to determine whether GSK2402968 given as a continuous dose and as an intermittent dose is effective and safe in the treatment of Duchenne muscular dystrophy.


Options:
A: Arm Label: Lisinopril; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lisinopril | Arm Label: Losartan; Type: ACTIVE_COMPARATOR; Interventions: Drug: Losartan | Intervention Type: DRUG; Name: Losartan; Assigned to Arm(s): Losartan | Intervention Type: DRUG; Name: Lisinopril; Assigned to Arm(s): Lisinopril
B: Arm Label: Continuous regimen; 6mg/kg once weekly; Type: EXPERIMENTAL; Interventions: Drug: GSK2402968, Drug: matched placebo | Arm Label: Intermittent regimen; 6mg/kg twice weekly; Type: EXPERIMENTAL; Interventions: Drug: GSK2402968, Drug: matched placebo | Intervention Type: DRUG; Name: GSK2402968; Assigned to Arm(s): Continuous regimen; 6mg/kg once weekly, Intermittent regimen; 6mg/kg twice weekly | Intervention Type: DRUG; Name: matched placebo; Assigned to Arm(s): Continuous regimen; 6mg/kg once weekly, Intermittent regimen; 6mg/kg twice weekly
C: Arm Label: Revatio (sildenafil); Type: EXPERIMENTAL; Interventions: Drug: Sildenafil | Arm Label: Placebo; Type: OTHER; Interventions: Drug: Sildenafil | Intervention Type: DRUG; Name: Sildenafil; Assigned to Arm(s): Placebo, Revatio (sildenafil)
D: Arm Label: eplerenone; Type: ACTIVE_COMPARATOR; Interventions: Drug: eplerenone | Arm Label: sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: eplerenone; Assigned to Arm(s): eplerenone | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): sugar pill

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Appropriate Controlled Feeding: a Single Blinded Prospective Randomised Study
Brief Summary: During patients' stay in the hospital, some of the patients may require artificial feeding for various reasons either through a vein or through a tube going directly to the gut. However, the amount of feeding that can be considered 'adequate' is unclear due to lack of research data. The current evidence the investigators have suggests that doctors might be giving patients more than they require, which might carry some risks. This hasn't been proven until now and there is no evidence as yet to show investigators exactly how much the doctors should feed patients.

The aim of the study is to see whether feeding patients less than what they are currently been feed is associated with better outcome.

The patients will be randomly (like tossing a coin) allocated into 2 groups. One group will get 100% of the current amount; the second group will get 60%. The investigators will then compare the groups to decide if feeding patients less than the current practice is associated with better outcomes.


Options:
A: Arm Label: Normocaloric feeding; Type: NO_INTERVENTION; Interventions: Other: Hypocaloric feeding | Intervention Type: OTHER; Name: Hypocaloric feeding; Assigned to Arm(s): Normocaloric feeding
B: Arm Label: SPN group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: SPN | Arm Label: Control gr; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: SPN; Assigned to Arm(s): SPN group
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zodin (drug) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Olive oil (placebo) | Intervention Type: DRUG; Name: Zodin (drug); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Olive oil (placebo); Assigned to Arm(s): 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Minimal (Trophic) Feeding, Dietary Supplement: Omega-3 Fatty Acids and Antioxidant Supplements | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Full Feeding, Dietary Supplement: Omega-3 Fatty Acids and Antioxidant Supplements | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Minimal (Trophic) Feeding, Dietary Supplement: Placebo | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Full Feeding, Dietary Supplement: Placebo | Intervention Type: BEHAVIORAL; Name: Minimal (Trophic) Feeding; Assigned to Arm(s): 1, 3 | Intervention Type: BEHAVIORAL; Name: Full Feeding; Assigned to Arm(s): 2, 4 | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega-3 Fatty Acids and Antioxidant Supplements; Assigned to Arm(s): 1, 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 3, 4

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter Double-bind Randomized Trial of Ferric Carboxymaltose With or Without Erythropoietin for the Prevention of Red-cell Transfusion in Hip Fracture Perioperative Period.
Brief Summary: In order to evaluate the efficacy of ferric carboxymaltose + erythropoietin versus ferric carboxymaltose versus placebo in reducing the percentage of patients who receive red-cell transfusion in the perioperative period of hip fracture, a multicenter, randomized, parallel groups, double-blind clinical trial in adult patients admitted for osteoporotic hip fracture is designed. Required sample size is of 87 patients per arm (87x3 = 261). Primary efficacy variable is the percentage of patients who receive red-cell transfusion during hospitalization; secondary end-points: average red-cell packs per patient,haemoglobin at 24 h and 72h after the intervention, at the time of hospital discharge and 60 days after hospital discharge, hospital stay and mortality during hospital-stay and 60 days afterwards. Adverse clinical events and side effects are assessed as safety variables. In addition health related quality of life will be measured at inclusion and after 60 days. A cost-efficacy analysis (by means of incremental cost-efficacy method using as a primary endpoint each patient not requiring transfusion, and as secondary end-point every patient who survived the index admission is performed). The investigators would like to demonstrate a double benefits: optimizing precious resource such as blood products and reducing complications arising from their use.


Options:
A: Arm Label: Iron Group; Type: EXPERIMENTAL; Interventions: Drug: Ferrous Sulfate | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Oral Tablet | Intervention Type: DRUG; Name: Ferrous Sulfate; Assigned to Arm(s): Iron Group | Intervention Type: DRUG; Name: Placebo Oral Tablet; Assigned to Arm(s): Placebo Group
B: Arm Label: Ferric carboxymaltose; Type: EXPERIMENTAL; Interventions: Drug: Ferric carboxymaltose, Drug: Normal saline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: Ferric carboxymaltose; Assigned to Arm(s): Ferric carboxymaltose | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): Ferric carboxymaltose, Placebo
C: Intervention Type: DRUG; Name: Iron Sucrose IV 200mg, once a week, for 5 weeks; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ferrous sulfate 200mg PO TID, for 8 weeks; Assigned to Arm(s): N/A
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: FE; Type: EXPERIMENTAL; Interventions: Drug: Ferric carboxymaltose | Arm Label: EPOFE; Type: EXPERIMENTAL; Interventions: Drug: Ferric carboxymaltose, Drug: Erythropoietin | Intervention Type: DRUG; Name: Ferric carboxymaltose; Assigned to Arm(s): EPOFE, FE | Intervention Type: DRUG; Name: Erythropoietin; Assigned to Arm(s): EPOFE | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness and Cost-effectiveness of a Ready-to-Use-Food (RUF) Supplement to Prevent Acute Malnutrition in Children Between 6-36 Months in Urban Chad
Brief Summary: The overall objective of this project is to assess the effectiveness and cost-effectiveness of RUF (ready-to-Use Food, Plumpy Doz(r)) to prevent moderate acute malnutrition in children aged 6-36 months if embedded in a program of conditional household food assistance.


Options:
A: Arm Label: Food-for-Training component; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Food-for-Training | Arm Label: Food-for-Training + RUF (Plumpy Doz(r)); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Plumpy Doz(r) - Ready-to-Use Food, Behavioral: Food-for-Training | Intervention Type: DIETARY_SUPPLEMENT; Name: Plumpy Doz(r) - Ready-to-Use Food; Assigned to Arm(s): Food-for-Training + RUF (Plumpy Doz(r)) | Intervention Type: BEHAVIORAL; Name: Food-for-Training; Assigned to Arm(s): Food-for-Training + RUF (Plumpy Doz(r)), Food-for-Training component
B: Intervention Type: DIETARY_SUPPLEMENT; Name: No food supplement; Assigned to Arm(s): N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Food supplement: fortified spread; Assigned to Arm(s): N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Food supplement: maize-soy flour; Assigned to Arm(s): N/A
C: Arm Label: MSPP Integrated Package; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Nutributter 3 Months, Integrated Package; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Nutributter Program, Other: Integrated Package | Arm Label: Nutributter 6 Months, Integrated Package; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Nutributter Program, Other: Integrated Package | Intervention Type: DIETARY_SUPPLEMENT; Name: Nutributter Program; Assigned to Arm(s): Nutributter 3 Months, Integrated Package, Nutributter 6 Months, Integrated Package | Intervention Type: OTHER; Name: Integrated Package; Assigned to Arm(s): Nutributter 3 Months, Integrated Package, Nutributter 6 Months, Integrated Package
D: Intervention Type: DIETARY_SUPPLEMENT; Name: PlumpyNut; Assigned to Arm(s): N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: PlumpyDoz; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Nutritional Supplementation (RUTF and Multi Micronutrient) in Preventing Malnutrition in Children 6-59 Months With Infection (Malaria, Pneumonia, Diarrhoea), a Randomized Controlled Trial in Nigeria
Brief Summary: The purpose of this study is to determine whether 14 days nutritional supplementation with Ready to use therapeutic Food (RUTF) or micronutrients alone to children having an infection will prevent malnutrition and reduce the frequency of morbidity.


Options:
A: Arm Label: Multiple Intervention Arm; Type: EXPERIMENTAL; Interventions: Drug: Albendazole, Dietary Supplement: Zinc, Dietary Supplement: Multiple Micronutrient Supplement | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Albendazole; Assigned to Arm(s): Multiple Intervention Arm | Intervention Type: DIETARY_SUPPLEMENT; Name: Zinc; Assigned to Arm(s): Multiple Intervention Arm | Intervention Type: DIETARY_SUPPLEMENT; Name: Multiple Micronutrient Supplement; Assigned to Arm(s): Multiple Intervention Arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Ready to Use Therapeutic Food (RUTF); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Ready to Use Therapeutic Food (RUTF) | Arm Label: Micronutrient Powder (MNP); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Micronutrient Powder (MNP) | Arm Label: no supplement; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Ready to Use Therapeutic Food (RUTF); Assigned to Arm(s): Ready to Use Therapeutic Food (RUTF) | Intervention Type: DIETARY_SUPPLEMENT; Name: Micronutrient Powder (MNP); Assigned to Arm(s): Micronutrient Powder (MNP)
C: Arm Label: Experimental: Ready to Use Terapeutic Food (RUTF); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Dietary Supplement: Nutrition supplement with RUTF or MNP | Arm Label: Multi Micronutrient Powder (MNP); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Dietary Supplement: Nutrition supplement with RUTF or MNP | Arm Label: no supplement; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Dietary Supplement: Nutrition supplement with RUTF or MNP; Assigned to Arm(s): Experimental: Ready to Use Terapeutic Food (RUTF), Multi Micronutrient Powder (MNP)
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Other: Nutritional Counselling and Education | Arm Label: B; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Micronutrient Supplementation without Zinc | Arm Label: C; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Micronutrient Supplementation with Zinc | Intervention Type: DIETARY_SUPPLEMENT; Name: Micronutrient Supplementation without Zinc; Assigned to Arm(s): B | Intervention Type: DIETARY_SUPPLEMENT; Name: Micronutrient Supplementation with Zinc; Assigned to Arm(s): C | Intervention Type: OTHER; Name: Nutritional Counselling and Education; Assigned to Arm(s): A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With NASH
Brief Summary: This is a controlled study to determine the effectiveness and safety of ethyl icosapentate (EPA-E) in the treatment of adult patients with non-alcoholic steatohepatitis (NASH).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: omega-3 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: omega-3, Behavioral: multi-domain intervention | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: multi-domain intervention, Drug: Placebo | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: omega-3; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: multi-domain intervention; Assigned to Arm(s): 2, 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3, 4
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo capsule | Arm Label: EPA-E 1800 mg/day; Type: EXPERIMENTAL; Interventions: Drug: EPA-E 300 mg capsule | Arm Label: EPA-E 2700 mg/day; Type: EXPERIMENTAL; Interventions: Drug: EPA-E 300 mg capsule | Intervention Type: DRUG; Name: Placebo capsule; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: EPA-E 300 mg capsule; Assigned to Arm(s): EPA-E 1800 mg/day | Intervention Type: DRUG; Name: EPA-E 300 mg capsule; Assigned to Arm(s): EPA-E 2700 mg/day
C: Arm Label: Lutein/Zeaxanthin; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lutein/zeaxanthin | Arm Label: DHA/EPA; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: DHA/EPA | Arm Label: Lutein/Zeaxanthin + DHA/EPA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lutein/zeaxanthin and DHA/EPA | Arm Label: Placebo/Control; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Lutein/zeaxanthin; Assigned to Arm(s): Lutein/Zeaxanthin | Intervention Type: DIETARY_SUPPLEMENT; Name: DHA/EPA; Assigned to Arm(s): DHA/EPA | Intervention Type: DRUG; Name: Lutein/zeaxanthin and DHA/EPA; Assigned to Arm(s): Lutein/Zeaxanthin + DHA/EPA
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Omega 3 (n-3 PUFA) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega 3 (n-3 PUFA); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: B